Marpai (MRAI) COO buys 100,000 shares, 200,000 warrants

Marpai, Inc. (MRAI) insider transaction: Chief Operating Officer Dallas Scrip reported a private placement purchase on 11/07/2025 of 100,000 shares of Class A common stock at $1.00 per share and common warrants to purchase up to 200,000 additional shares.

Rhea-AI Filing Summary

Marpai, Inc. (MRAI) insider transaction: Chief Operating Officer Dallas Scrip reported a private placement purchase on 11/07/2025 of 100,000 shares of Class A common stock at $1.00 per share and common warrants to purchase up to 200,000 additional shares. The warrants are exercisable immediately at $1.00 per share and remain exercisable for three years from the 11/07/2025 issuance date, expiring on 11/06/2028.

The securities are held indirectly by the Dallas S. Scrip and Michelle R. Script Trust, for which the reporting person and spouse serve as co‑trustees with shared voting and investment control.

Insider Trade Summary

Net Buyer: 200,000 shares

Net Buy 2 txns

Insider Scrip Dallas

Role Chief Operating Officer

Bought 200,000 shs ($0.00)

Type	Security	Shares	Price	Value
Purchase	Common Warrants to purchase Shares of Common Stock	200,000	$0.00	$0.00
Grant/Award	Class A Common Stock	100,000	$1.00	$100K

Holdings After Transaction: Common Warrants to purchase Shares of Common Stock — 200,000 contracts (Indirect, By Dallas S. Scrip and Michelle R. Script Trust); Class A Common Stock — 100,000 shares (Indirect, By Dallas S. Scrip and Michelle R. Script Trust)

Footnotes (2)

1. F1. On November 7, 2025, Marpai Inc. (the "Company") entered into a Securities Purchase Agreement for a private placement offering, in which the reporting person purchased 100,000 shares of common stock of the Company and common warrants to purchase up to 200,000 shares of common stock of the Company. The purchase price for each share of common stock and accompanying common warrant is $1.00. The common warrants have an exercise price of $1.00 per share, can be exercised immediately following the closing of the private placement offering and will be exercisable for three years following the date of issuance.
2. F2. The securities are held by the Dallas S. Scrip and Michelle R. Script Trust, of which the reporting person and spouse are co-trustees and share investment and voting control.

FAQ

What did Marpai (MRAI) disclose in this Form 4?

The COO reported buying 100,000 shares at $1.00 and acquiring warrants for 200,000 shares in a private placement on 11/07/2025.

What are the terms of the MRAI warrants reported?

The common warrants are exercisable immediately at $1.00 per share and are exercisable for three years, expiring on 11/06/2028.

How is the Marpai (MRAI) ownership held by the reporting person?

Indirectly via the Dallas S. Scrip and Michelle R. Script Trust, where the reporting person and spouse are co‑trustees sharing control.

What is the insider’s role at Marpai (MRAI)?

The reporting person is Chief Operating Officer of Marpai, Inc.

Was this a market purchase of MRAI stock?

No. It was part of a private placement under a Securities Purchase Agreement on 11/07/2025.

How many shares could be acquired if the warrants are exercised?

Up to 200,000 shares of common stock at an exercise price of $1.00 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 06:48 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scrip Dallas

(Last) (First) (Middle)

C/O MARPAI, INC.

615 CHANNELSIDE DRIVE, SUITE 207

(Street)

TAMPA FL 33602

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Marpai, Inc. [ MRAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/07/2025		A		100,000(1)	A	$1	100,000	I	By Dallas S. Scrip and Michelle R. Script Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Warrants to purchase Shares of Common Stock	$1	11/07/2025		P		200,000		11/07/2025	11/06/2028	Shares of Common Stock	200,000	(1)	200,000	I	By Dallas S. Scrip and Michelle R. Script Trust(2)

Explanation of Responses:

1. On November 7, 2025, Marpai Inc. (the "Company") entered into a Securities Purchase Agreement for a private placement offering, in which the reporting person purchased 100,000 shares of common stock of the Company and common warrants to purchase up to 200,000 shares of common stock of the Company. The purchase price for each share of common stock and accompanying common warrant is $1.00. The common warrants have an exercise price of $1.00 per share, can be exercised immediately following the closing of the private placement offering and will be exercisable for three years following the date of issuance.

2. The securities are held by the Dallas S. Scrip and Michelle R. Script Trust, of which the reporting person and spouse are co-trustees and share investment and voting control.

	/s/ Dallas Scrip	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.